oncgnostics GmbH, a Jena, Germany-based developer of molecular cancer diagnostics, has raised seed funding of undisclosed amount from High-Tech Gründerfonds and STIFT.
The seed funding enables oncgnostics to develop diagnostically usable and saleable tests, with the aim to launch them in cooperation with HPV test suppliers.
Founded in Jena by Professor Matthias Dürst, leader of the gynaecological molecular biology lab, Alfred Hansel, Martina Schmitz, and the economist Kerstin Brox, on Feb 1st, 2012, the company focuses on the development of accurate molecular diagnostic tests for use in cancer screening, therapy decision, and follow-up care.
During implementation of the project oncgnostics received exceptional support by the gynecology department of the university hospital Jena.
FinSMEs
17/04/2012